Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study.

Richard L Hengel; Timothy E Ritter; Ramesh V Nathan; Lucinda J Van Anglen; Claudia P Schroeder; Ryan J Dillon; Stephen W Marcella; Kevin W Garey

doi:10.1093/OFID/OFAA097

Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study.

Richard L Hengel
, Timothy E Ritter
, Ramesh V Nathan
, Lucinda J Van Anglen
, Claudia P Schroeder
, Ryan J Dillon
, Stephen W Marcella
, Kevin W Garey

Atlanta ID Group, Atlanta, Georgia
GI Alliance, Southlake, Texas, USA.
Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, California, USA.
Healix Infusion Therapy, LLC., Sugar Land, Texas, USA.
Merck & Co.
University of Houston

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Open Forum Infectious Diseases
Volume	7
Issue number	4
DOIs	https://doi.org/10.1093/OFID/OFAA097
State	Published - Mar 19 2020
Externally published	Yes

Disciplines

Medicine and Health Sciences
Internal Medicine

Access to Document

10.1093/OFID/OFAA097License: Unspecified

Cite this

@article{3e91ec6539d745edae0d8befe869c297,

title = "Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study.",

author = "Hengel, \{Richard L\} and Ritter, \{Timothy E\} and Nathan, \{Ramesh V\} and \{Van Anglen\}, \{Lucinda J\} and Schroeder, \{Claudia P\} and Dillon, \{Ryan J\} and Marcella, \{Stephen W\} and Garey, \{Kevin W\}",

note = "Clostridioides difficile causes \textasciitilde{}500 000 infections in the United States and is responsible for 44 000 deaths and \$5.4 billion in health care costs annually [ 1]. Up to 25\% of patients with initial C.",

year = "2020",

month = mar,

day = "19",

doi = "10.1093/OFID/OFAA097",

language = "American English",

volume = "7",

journal = "Open Forum Infectious Diseases",

number = "4",

}

TY - JOUR

T1 - Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study.

AU - Hengel, Richard L

AU - Ritter, Timothy E

AU - Nathan, Ramesh V

AU - Van Anglen, Lucinda J

AU - Schroeder, Claudia P

AU - Dillon, Ryan J

AU - Marcella, Stephen W

AU - Garey, Kevin W

N1 - Clostridioides difficile causes ~500 000 infections in the United States and is responsible for 44 000 deaths and $5.4 billion in health care costs annually [ 1]. Up to 25% of patients with initial C.

PY - 2020/3/19

Y1 - 2020/3/19

UR - https://academic.oup.com/ofid/article/7/4/ofaa097/5809989

U2 - 10.1093/OFID/OFAA097

DO - 10.1093/OFID/OFAA097

M3 - Article

VL - 7

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 4

ER -

Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study.

Disciplines

Access to Document

Other files and links

Cite this